Nusajaya, Johor, Malaysia
Stelis Biopharma has selected Bio-XCell to construct a $60 million biopharmaceutical manufacturing facility in Nusajaya in the Johor region of Malaysia. Providing mammalian and microbial production suites, the 140,000-sf project will feature next-generation, single-use bioprocessing technologies. Completion is expected in late 2016 with operations commencing in mid-2017. Stelis Biopharma is a wholly-owned subsidiary of Strides Arcolab.
